© 2018 Miraculo Inc. All Rights Reserved
Efficacy And Safety Of The Weight-loss Drug Rimonabant: A Meta-analysis Of Randomised Trials.
Cannabinoids are found in the marijuana plant (cannabis sativa) and are said to be effective in pain management from pain symptoms such as:
A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain.
Cannabinoids for these receptors include the endocannabinoid system, that is produced in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non-psychotic effect. This paper will look at the synthetic cannabinoid rimonabant and its efficacy and safety as a weight loss drug.
Since the prevalence of obesity continues to increase, there is a demand for efficient and safe anti-obesity drugs that can make and keep a steady rate of weight loss and improve comorbidity. The researchers in this study did a meta-analysis of all published randomised regulated experiments to test the effectiveness and safety of the newly approved anti-obesity synthetic cannabinoid rimonabant.
Researchers collated data from four double-blind, randomised regulated experiments with 4105 people that compared 20 mg per day rimonabant with placebo. Subjects that were administered rimonabant had a 4·7 kg (95% CI 4·1–5·3 kg; p<0·0001) bigger weight loss after 1 year than did those administered placeboes. Rimonabant caused more side effects than the placebo. Patients given synthetic cannabinoids were 2·5 times more likely to stop the treatment because of a depressive frame of mind syndromes than were those administered placebo. More so, anxiety made more subjects to stop treatment in rimonabant groups than in placebo groups. The findings from this study indicate that 20 mg per day rimonabant greater the risk of psychiatric side effects, such as depressed mood disorders and anxiety.
These clinical discoveries go hand in hand with findings of animal experiments that implicate the CB1 receptor in controlling of antidepressant-like or anxiolytic-like impacts of the endocannabinoid network. Inhibition of the destruction of the endogenous cannabinoid anandamide has an antidepressant-like impact in rodents; this impact was stopped by rimonabant. In rodents exposed to stress brought on by swimming, another CB1 antagonist impaired the reduction in corticosterone secretion that concludes from exposure to tricyclic antidepressants. Mice that were either genetically lacking for an enzyme that destroys anandamide or gained a selective inhibitor of this enzyme showed decreased anxiety-like behaviour; furthermore, this impact was stopped by rimonabant.
This research consistently displayed that pharmacological stopping of the CB1 receptor destroyed the antidepressant-reducing or anxiety-reducing methods of endocannabinoids. However, some abnormalities in animal experiments should be taken into account, since some studies have indicated that rimonabant might have antidepressant or anxiolytic abilities. Another look that might give a different physiological basis for increased mood syndromes seen with greatest weight-loss comes from reports that leptin, the adipose-derived hormone, had an antidepressant ability after intrahippocampal but not hypothalamic injection.10.1.1.612.5470